Table 1.
Baseline characteristics of all the patients (N = 40).
| Variable | N (%) or median (IQR) |
|---|---|
| Age, years | 62 (58, 70) |
| Sex | |
| Male | 22 (55.0%) |
| Female | 18 (45.0%) |
| ECOG Performance status | |
| 0 | 26 (65.0%) |
| 1 | 10 (25.0%) |
| 2 | 4 (10.0%) |
| Primary tumor location | |
| Head | 14 (35.0%) |
| Body | 14 (35.0%) |
| Tail | 12 (30.0%) |
| Disease stage | |
| Locally advanced | 5 (12.5%) |
| Metastatic | 35 (87.5%) |
| Site of metastasis | |
| Liver | 22 (55.0%) |
| Peritoneum | 14 (35.0%) |
| Lung | 4 (10.0%) |
| Baseline laboratory findings | |
| CEA—U/mL | 6.5 (4.2, 19.5) |
| CA 19-9—U/mL | 2155 (194, 7996) |
| Time on FOLFIRINOX (months) | 8.2 (4.3, 15.5) |
| Number of FOLFIRINOX cycle | 15 (7, 20) |
| Reason for FOLFIRINOX discontinuation | |
| Radiographic progression | 40 (100%) |
| Oxaliplatin neurotoxicity at enrollment | 18 (45.0%) |
CA 19-9, Carbohydrate antigen 19-9; CEA, Carcinoembryonic antigen; ECOG, Eastern Cooperative Oncology Group; IQR, interquartile range.